Boston Scientific completes enrollment in MADIT-CRT trial

Interventional device developer Boston Scientific has completed patient enrollment in a heart failure trial, the Natick, MA-based company said.

The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) includes 1,820 patients and uses the company's resynchronization therapy defibrillators in a new population of heart failure patients: heart attack survivors and those with other forms of impaired heart function, Boston Scientific said.

Related Reading

Boston Scientific earns Canadian approval for Taxus, April 17, 2008

Boston Scientific to buy CryoCor, April 16, 2008

Boston Scientific inks deal with Surgi-Vision, April 15, 2008

Boston Scientific loses patent suit, February 13, 2008

Cordis wins heart stent patent appeal, January 11, 2008

Copyright © 2008

Page 1 of 180
Next Page